Fospropofol

Drug Profile

Fospropofol

Alternative Names: Aquavan®; Fospropofol disodium; GPI 15715; HX0507; Lusedra; PQ 1002

Latest Information Update: 25 May 2017

Price : $50

At a glance

  • Originator ProQuest Pharmaceuticals
  • Developer Eisai Co Ltd; Yichang Humanwell Pharmaceutical
  • Class Anaesthetics; Hypnosedatives; Phenols; Small molecules
  • Mechanism of Action GABA receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Sedation

Most Recent Events

  • 25 May 2017 No recent reports on development identified - Phase-II for Sedation in China (IV)
  • 16 Nov 2009 Launched for Sedation in USA (IV)
  • 14 Dec 2008 Registered for Sedation in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top